- Discovery of a Novel Highly Selective Histamine H4 Receptor Antagonist for the Treatment of Atopic Dermatitis
-
The histamine H4 receptor (H4R), a member of the G-protein coupled receptor family, has been considered as a potential therapeutic target for treating atopic dermatitis (AD). A large number of H4R antagonists have been disclosed, but no efficient agents controlling both pruritus and inflammation in AD have been developed yet. Here, we have discovered a novel class of orally available H4R antagonists showing strong anti-itching and anti-inflammation activity as well as excellent selectivity against off-targets. A pharmacophore-based virtual screening system constructed in-house successfully identified initial hit compound 9, and the subsequent homology model-guided optimization efficiently led us to discover pyrido[2,3-e]tetrazolo[1,5-a]pyrazine analogue 48 as a novel chemotype of a potent and highly selective H4R antagonist. Importantly, orally administered compound 48 exhibits remarkable efficacy on antipruritus and anti-inflammation with a favorable pharmacokinetic (PK) profile in several mouse models of AD. Thus, these data strongly suggest that our compound 48 is a promising clinical candidate for treatment of AD.
- Ko, Kwangseok,Kim, Hye-Jung,Ho, Pil-Su,Lee, Soon Ok,Lee, Ji-Eun,Min, Cho-Rong,Kim, Yu Chul,Yoon, Ju-Han,Park, Eun-Jung,Kwon, Young-Jin,Yun, Jee-Hun,Yoon, Dong-Oh,Kim, Jung-Sook,Park, Woul-Seong,Oh, Seung-Su,Song, Yu-Mi,Cho, Woon-Ki,Morikawa, Kazumi,Lee, Kyoung-June,Park, Chan-Hee
-
supporting information
p. 2949 - 2961
(2018/04/23)
-
- PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS
-
This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
- -
-
Paragraph 0339
(2018/08/01)
-
- NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES
-
The present invention relates to novel heterocyclic compounds useful in preparing drugs for treatment of diseases associated with various functions of the histamine 4 receptor. Especially, the said drugs are useful for treatment of inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itch, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritic pain, autoimmune thyroid disease, immune-mediated (also known as type I) diabetes, lupus, post-operative adhesions, vestibular disorders and cancer.
- -
-
Paragraph 0842-0844
(2014/10/29)
-
- IMIDAZOPYRIDIN-2-ONE DERIVATIVES
-
A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof.
- -
-
-
- Synthesis of a 6-methyl-7-deaza analogue of adenosine that potently inhibits replication of polio and dengue viruses
-
Bioisosteric deaza analogues of 6-methyl-9-β-d-ribofuranosylpurine, a hydrophobic analogue of adenosine, were synthesized and evaluated for antiviral activity. Whereas the 1-deaza and 3-deaza analogues were essentially inactive in plaque assays of infectivity, a novel 7-deaza-6-methyl-9-β-d- ribofuranosylpurine analogue, structurally related to the natural product tubercidin, potently inhibited replication of poliovirus (PV) in HeLa cells (IC50 = 11 nM) and dengue virus (DENV) in Vero cells (IC50 = 62 nM). Selectivity against PV over cytotoxic effects to HeLa cells was >100-fold after incubation for 7 h. Mechanistic studies of the 5′-triphosphate of 7-deaza-6-methyl-9-β-d-ribofuranosylpurine revealed that this compound is an efficient substrate of PV RNA-dependent RNA polymerase (RdRP) and is incorporated into RNA mimicking both ATP and GTP.
- Wu, Runzhi,Smidansky, Eric D.,Oh, Hyung Suk,Takhampunya, Ratree,Padmanabhan, Radhakrishnan,Cameron, Craig E.,Peterson, Blake R.
-
p. 7958 - 7966
(2011/03/19)
-
- ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF
-
The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives substantially enriched in an enantiomer of formula (I): and compounds of formula (IH) wherein R3, R4, R5, R6, R7, R13a, R13b, R14a, R14b, P, Q, V, W, X, Y, Z and a are as defined in the description, compositions thereof, processes for their preparation and their uses as pesticides.
- -
-
Page/Page column 86
(2010/06/13)
-
- ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF
-
The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives of formula (I):wherein R3, R4, R5, R6, R7, P, Q, V, W, X, Y, Z and a are as defined in the description, compositions thereof, processes for their preparation and their uses as pesticides.
- -
-
Page/Page column 109
(2009/01/20)
-
- Synthesis and biological evaluation of pyrido[2,3-b]pyrazine and pyrido[2,3-b]pyrazine-N-oxide as selective glycine antagonists
-
Pyrido[2,3-b]pyrazines and pyrido[2,3-b]pyrazines-N-oxides have been synthesized and evaluated for in vitro/in vivo antagonistic activity at the glycine site on the NMDA receptor.
- Cugola, Alfredo,Donati, Daniele,Guarneri,Micheli, Fabrizio,Missio, Andrea,Pecunioso, Angelo,Reggiani, Angelo,Tarzia,Zanirato
-
p. 2749 - 2754
(2007/10/03)
-
- Diaminopyridine compounds and methods of use
-
The present invention relates to compositions and method for inhibiting nonenzymatic cross-linking (protein aging) which contain diaminopyridines and derivates thereof. Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.
- -
-
-